Literature DB >> 22197377

Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin.

Susan D Orwig1, Christopher W Perry, Laura Y Kim, Katherine C Turnage, Rong Zhang, Douglas Vollrath, Ingeborg Schmidt-Krey, Raquel L Lieberman.   

Abstract

Myocilin is a protein found in the extracellular matrix of trabecular meshwork tissue, the anatomical region of the eye involved in regulating intraocular pressure. Wild-type (WT) myocilin has been associated with steroid-induced glaucoma, and variants of myocilin have been linked to early-onset inherited glaucoma. Elevated levels and aggregation of myocilin hasten increased intraocular pressure and glaucoma-characteristic vision loss due to irreversible damage to the optic nerve. In spite of reports on the intracellular accumulation of mutant and WT myocilin in vitro, cell culture, and model organisms, these aggregates have not been structurally characterized. In this work, we provide biophysical evidence for the hallmarks of amyloid fibrils in aggregated forms of WT and mutant myocilin localized to the C-terminal olfactomedin (OLF) domain. These fibrils are grown under a variety of conditions in a nucleation-dependent and self-propagating manner. Protofibrillar oligomers and mature amyloid fibrils are observed in vitro. Full-length mutant myocilin expressed in mammalian cells forms intracellular amyloid-containing aggregates as well. Taken together, this work provides new insights into and raises new questions about the molecular properties of the highly conserved OLF domain, and suggests a novel protein-based hypothesis for glaucoma pathogenesis for further testing in a clinical setting.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197377      PMCID: PMC3323732          DOI: 10.1016/j.jmb.2011.12.016

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  90 in total

1.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

2.  Ultrastructural localization of myocilin in human trabecular meshwork cells and tissues.

Authors:  J Ueda; K K Wentz-Hunter; E L Cheng; T Fukuchi; H Abe; B Y Yue
Journal:  J Histochem Cytochem       Date:  2000-10       Impact factor: 2.479

3.  A cellular assay distinguishes normal and mutant TIGR/myocilin protein.

Authors:  Z Zhou; D Vollrath
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

4.  Identification of the region in the N-terminal domain responsible for the cytoplasmic localization of Myoc/Tigr and its association with microtubules.

Authors:  M Mertts; S Garfield; K Tanemoto; S I Tomarev
Journal:  Lab Invest       Date:  1999-10       Impact factor: 5.662

5.  Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth.

Authors:  J McLaurin; T Franklin; X Zhang; J Deng; P E Fraser
Journal:  Eur J Biochem       Date:  1999-12

6.  Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma.

Authors:  D S Lam; Y F Leung; J K Chua; L Baum; D S Fan; K W Choy; C P Pang
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-05       Impact factor: 4.799

Review 7.  Folding versus aggregation: polypeptide conformations on competing pathways.

Authors:  Thomas R Jahn; Sheena E Radford
Journal:  Arch Biochem Biophys       Date:  2007-06-08       Impact factor: 4.013

8.  Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma.

Authors:  Yu Zhou; Oleg Grinchuk; Stanislav I Tomarev
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

9.  Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen.

Authors:  Annalisa Relini; Silvia De Stefano; Silvia Torrassa; Ornella Cavalleri; Ranieri Rolandi; Alessandra Gliozzi; Sofia Giorgetti; Sara Raimondi; Loredana Marchese; Laura Verga; Antonio Rossi; Monica Stoppini; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2007-12-03       Impact factor: 5.157

Review 10.  One step at a time: endoplasmic reticulum-associated degradation.

Authors:  Shruthi S Vembar; Jeffrey L Brodsky
Journal:  Nat Rev Mol Cell Biol       Date:  2008-11-12       Impact factor: 94.444

View more
  30 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Differential Misfolding Properties of Glaucoma-Associated Olfactomedin Domains from Humans and Mice.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Yiming Wang; Iramofu M Dominic; Carol K Hall; Raquel L Lieberman
Journal:  Biochemistry       Date:  2019-03-12       Impact factor: 3.162

3.  Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma.

Authors:  Andrew R Stothert; Amirthaa Suntharalingam; Dustin J E Huard; Sarah N Fontaine; Vincent M Crowley; Sanket Mishra; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

4.  A conservative mutant of a proteolytic fragment produced during fibril formation enhances fibrillogenesis.

Authors:  Vladimir V Egorov; Dmitry V Lebedev; Aram A Shaldzhyan; Alexey K Sirotkin; Andrey N Gorshkov; Olga A Mirgorodskaya; Natalia A Grudinina; Andrey V Vasin; Michael M Shavlovsky
Journal:  Prion       Date:  2014       Impact factor: 3.931

5.  Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations.

Authors:  Shannon E Hill; Michelle S Kwon; Mackenzie D Martin; Amirthaa Suntharalingam; Anthony Hazel; Chad A Dickey; James C Gumbart; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2019-07-02       Impact factor: 5.157

6.  The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence.

Authors:  Shannon E Hill; Rebecca K Donegan; Raquel L Lieberman
Journal:  J Mol Biol       Date:  2013-12-09       Impact factor: 5.469

7.  Mutated myocilin and heterozygous Sod2 deficiency act synergistically in a mouse model of open-angle glaucoma.

Authors:  Myung Kuk Joe; Naoki Nakaya; Mones Abu-Asab; Stanislav I Tomarev
Journal:  Hum Mol Genet       Date:  2015-03-03       Impact factor: 6.150

8.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

9.  Simulations and Experiments Delineate Amyloid Fibrilization by Peptides Derived from Glaucoma-Associated Myocilin.

Authors:  Yiming Wang; Yuan Gao; Shannon E Hill; Dustin J E Huard; Moya O Tomlin; Raquel L Lieberman; Anant K Paravastu; Carol K Hall
Journal:  J Phys Chem B       Date:  2018-05-21       Impact factor: 2.991

10.  Epitope mapping of commercial antibodies that detect myocilin.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Michael P Fautsch; Raquel L Lieberman
Journal:  Exp Eye Res       Date:  2018-05-09       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.